Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J’s Darzalex Could Gain Another Breakthrough Tag with New Study Data

By Ryan Bushey | October 10, 2016

The good news continues rolling in for Johnson & Johnson.

New study results indicate the drug Darzalex could be a valid treatment regimen for multiple myeloma patients at all stages of the diseases, reported FiercePharma.

Investigators running this trial compared the Darzalex combination therapy against Celgene’s Revlimid and dexamethasone in a trial with 569 patients.

Results showed the Darzalex cocktail was the superior alternative for treatment leading to complete response rate of 43.1 percent in patients participating in this trial. By contrast, volunteers taking Revlimid and dexamethasone experience a 19.2 percent response rate.

Furthermore, Darzalex, “also cut the risk of disease progression an impressive 63 percent compared with the two-drug approach,” according to FiercePharma.

J&J gained a breakthrough designation for the Darzalex combinations in July 2016 for patients who have received at least one prior therapy. Positive data like this could support the company’s case for another label expanding the patient pool for people who tend to stay on these therapies for longer periods of time.

Both authors of this study, Dr. S. Vincent Rajkumar and Dr. Robert A. Kyle, wrote a commentary in the New England Journal of Medicine saying that this drug was a “landmark advance” and could become the new standard treatment of care for multiple myeloma within the next few years.

This announcement comes on the heels of J&J’s next-gen psoriasis drug beating out Humira in a late-stage study setting the stage for a competition against AbbVie’s prized product.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE